BTIG analyst Ryan Zimmerman maintained a Buy rating on Vericel (VCEL) yesterday and set a price target of $21.00. The company’s shares closed last Tuesday at $15.88.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 11.8% and a 54.5% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Zimmer Biomet Holdings.
Vericel has an analyst consensus of Strong Buy, with a price target consensus of $25.00.
See today’s analyst top recommended stocks >>
Based on Vericel’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $20.01 million and GAAP net loss of $8.27 million. In comparison, last year the company earned revenue of $26.15 million and had a GAAP net loss of $19.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
